Concepedia

H. Huber

HH

Statistics

Publications

6

Citations

152

H-Index

6

Active since

1993

Affiliations

Heidelberg University(Current)

Universität Innsbruck

University of Freiburg

University Hospital Ulm

University Hospital Cologne

H. Huber is an author at Heidelberg University specializing in medicine, oncology, and cancer immunotherapy.

Publications per year

1993–2023

6

Publications

6

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/<i>TP53</i>mut

H. Huber, Eugen Tausch, Christof Schneider et al. · Blood · 2023 · 48 citations · Full text

, , +11

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

H. Huber, Simone Edenhofer, Julia von Tresckow et al. · Blood · 2022 · 46 citations · Full text

, , +8

Treatment with Low Dose Human Recombinant Interferon-Alpha-2-ARG Induces Complete Remission in Patients with Hairy Cell Leukemia

Günther Gastl, H. Denz, C. Abbrederis et al. · Onkologie · 2009 · 21 citations · Full text

, , +11

Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group.

J. Thaler, Günther Gastl, Thomas Fluckinger et al. · PubMed · 1993 · 13 citations

, , +13

Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in “ultra High-risk” CLL: Final Results from the CLL2O Phase II Study

Stephan Stilgenbauer, Florence Cymbalista, Véronique Leblond et al. · Blood · 2014 · 13 citations

, , +7

1–5 of 6